COMMUNIQUÉS West-GlobeNewswire

Coherus BioSciences Announces New Employment Inducement Grants
07/02/2019
REDWOOD CITY, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective February 6, 2019, the compensation committee of the company’s board of directors granted [...]
Vystar to Resume Production of Rx3000 UV Light Air Purifiers for Use in Hospitals, Healthcare Facilities
07/02/2019
Destroys on first pass more than 99.97% of harmful airborne viruses and bacteria. Inactivates pathogens that cause measles, the common cold, MRSA (staph), whooping cough, TB, pneumonia and other antibiotic-resistant and [...]
BioAegis Therapeutics Expands Phase 1b/2a Community-Acquired Pneumonia Study to the Republic of Georgia —Successfully Completes Second of Four Dosing Cohorts
07/02/2019
MORRISTOWN, N.J., Feb. 07, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announced that patient enrollment is underway in a Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN) in Community-Acquired [...]
Nemaura Medical Announces Grant of U.S. Patent for SugarBEAT® Glucose Sensing Algorithm
07/02/2019
Loughborough, England – February 7, 2019 – Nemaura Medical Inc. (NASDAQ: NMRD) nemauramedical.com , a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible [...]
Third Study Verifies Milestone Scientific’s CompuFlo® Instrument Differentiates False Loss of Resistance During Epidural Blocks
07/02/2019
Easier, more reliable identification essential to reducing failed epidurals and complications LIVINGSTON, N.J., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS) today announced a new 120-patient [...]
NewLink Genetics to Host Its Fourth Quarter and Full Year 2018 Financial Results Conference Call on February 27, 2019
07/02/2019
AMES, Iowa, Feb. 07, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will release its fourth quarter and full year 2018 financial results on Wednesday, February 27, 2019. The [...]
Fluidigm Announces Co-Marketing Agreement with Indica Labs to Offer Platform for Imaging Mass Cytometry Data Analysis to Aid Novel Digital Pathology Investigations
07/02/2019
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM) and Indica Labs, Inc., today announced a co-marketing relationship for scalable and simple-to-use tissue image analysis [...]
Devimistat (CPI-613®) to be Explored in a New Combination for T-Cell Lymphoma Treatment as Part of Stand Up To Cancer’s T-Cell Lymphoma “Dream Team Research Grant”
07/02/2019
This study will be conducted under the ‘Tailoring CAR-based immunotherapy strategies to T-Cell Lymphoma’ project Newark, NJ, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a [...]
Precision Therapeutics’ Skyline Medical Division Expands Presence in Australia with Three New STREAMWAY Systems at Wangaratta Hospital in Victoria
07/02/2019
MINNEAPOLIS, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announces its Skyline Medical division, producer of the FDA-approved and CE-marked STREAMWAY [...]
Innovate Biopharmaceuticals Announces Presentation at BIO CEO & Investor Conference
07/02/2019
Presentation will Highlight Progress in Celiac Disease Phase 3 Trial Timeline and NASH RALEIGH, N.C., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT) a clinical stage biotechnology [...]
Fluidigm Announces Participation in Life Science/Pharma and Academic Consortium to Study T Cell-Driven Immune-Mediated Inflammatory Diseases
07/02/2019
Gaining insights into inflammatory bowel disease through mass cytometry and Imaging Mass Cytometry analysis of the human mucosal immune system Research aimed at more precise treatments for IMIDs using existing therapies [...]
Aleafia Health Helps Patients & Investors with Revenue Generating Research -- CFN Media
07/02/2019
SEATTLE, Wash., Feb. 07, 2019 (GLOBE NEWSWIRE) -- -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces [...]
Uptick Newswire Hosts Digipath, Inc. on the Stock Day Podcast to Discuss Their Increasing Revenues and the Launch of GroSciences
07/02/2019
PHOENIX, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Uptick Newswire Stock Day Podcast welcomed Digipath, Inc. (DIGP), a service-oriented independent testing laboratory, data and media firm focused on the developing cannabis and [...]
Auxly Announces Termination of FSD Pharma Joint Venture
07/02/2019
VANCOUVER, British Columbia, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX.V - XLY) (" Auxly " or the " Company ") today announced the termination of the definitive agreement dated March 3, 2018 (the [...]
Equillium Granted U.S. FDA Orphan Drug Designations for EQ001 (itolizumab) for both the Prevention and Treatment of Acute Graft-Versus-Host Disease
07/02/2019
LA JOLLA, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that the U.S. Food and Drug [...]
Momenta Pharmaceuticals Announces Oral Presentation of New Data for M281 at the Society for Maternal-Fetal Medicine 2019 Annual Meeting
07/02/2019
Study highlights ability of M281 to inhibit transfer of immunoglobulin G from maternal to fetal circulation in ex vivo placental perfusion model M281 currently being evaluated in an international Phase 2 study in [...]
Evelo Biosciences to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, February 14, 2019
07/02/2019
CAMBRIDGE, Mass., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing monoclonal microbials, a potential new modality of oral biologic [...]
Forty Seven Inc. to Present at Guggenheim Healthcare Talks Idea Forum | Oncology Day
07/02/2019
MENLO PARK, Calif. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today [...]
Replimune to Present at Two Upcoming Investor Conferences
07/02/2019
WOBURN, Mass., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immunotherapies derived from its Immulytic™ platform, today announced that Robert Coffin [...]

Pages